ASH 2025: Milder chemo works for rare, aggressive lymphoma
Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive…
Browsing: ASH
ASH 2025: New data highlights promise of pivekimab sunirine in two aggressive blood cancers
Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing…
ASH 2025: Study connects Agent Orange exposure to earlier and more severe cases of myelodysplastic syndrome
A new national study shows for the first time that people exposed to Agent Orange…
ASH 2025: New combination approach aims to make CAR T more durable in lymphoma
A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell…
ASH 2025: ‘Ready-made’ T-cell gene therapy tackles ‘incurable’ T-cell leukaemia
A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College…
ASH 2025: Major treatment overhauls for acute myeloid leukaemia
A new generation of targeted treatments and gentler chemotherapy options for older adults with a…
ASH 2024: Preclinical study shows targeted drug strengthens the power of CAR T-cell therapy in two paediatric leukaemias
A preclinical study led by a faculty member at Roswell Park Comprehensive Cancer Center shows…
ASH 2024: Smoking linked with genetic mutations that worsen myelodysplastic syndromes
For the first time, researchers have illuminated how smoking – a known risk factor for…
ASH 2024: A fibre-rich diet may help prevent complications after stem cell transplant
Consuming a high-fiber diet after undergoing stem cell transplantation could help to reduce the risk…
ASH 2024: Study reveals how venetoclax boosts immune response to CAR T for chronic lymphocytic leukaemia
Research out of Roswell Park Comprehensive Cancer Center has shed light on how the drug…